Abstract

Ferroptosis: A new perspective in the diagnosis and treatment of coronary atherosclerotic heart disease

Author(s): Hong Fang, Omer Cavdar, Chi Liu, Zhiping Yao

Ferroptosis is an iron dependent lipid Reactive Oxygen Species (ROS) induced form of non-apoptotic cell death. It is governed by three antioxidant axes, such as the cyst(e)ine/GSH/GPX4 axis, the GCH1/BH4/DHFR axis, and the FSP1/CoQ10 axis. Emerging evidence has revealed that disorders of iron metabolism are the common denominator in the occurrence and development of diverse cardiovascular disease, including atherosclerosis, myocardial Ischemia Reperfusion and (I/R), and myocardial infarction. Some genes/proteins that are involved in lipid metabolism have been used as biomarkers of Ferroptosis. Those biomarkers have facilitated the development of potential methods for disease diagnosis. Iron chelators, antioxidants, Ferroptosis inhibitors, and genetic manipulations may alleviate Coronary Atherosclerotic Heart Disease (CHD) by blocking Ferroptosis pathways. Our found also suggest that Angiotensin Type1/2 Receptors (AT1/2R) blocker may inhibit Ferroptosis of vascular endothelial cells. Thus, suppression of Ferroptosis is a potential therapeutic option for CHD. Here, we aimed to highlight the effects of Ferroptosis in CHD and summarize new diagnoses and treatments based on Ferroptosis of CHD.